NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novavax Inc (NVAX) is not a strong buy for a beginner, long-term investor at this time. While there are some positive catalysts such as a bullish moving average and recent price target increases by analysts, the company's financial performance and lack of significant trading signals suggest that it is better to hold off on investing in this stock for now. The investor's funds can be better allocated to assets with stronger growth potential and clearer positive momentum.
The stock shows a bullish moving average trend (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive, indicating slight bullish momentum. However, the RSI is neutral at 34.059, and the stock is trading below the pivot level of 8.473, suggesting limited immediate upside potential. Key support levels are at 8.086 and 7.846, with resistance at 8.861 and 9.101.
Analysts have raised price targets, with some maintaining a Buy rating.
The company's pivot to a high-margin licensing model and agreements with Pfizer show potential for future revenue growth.
Gross margin increased significantly YoY to 84.98%.
Net income and EPS have dropped significantly YoY, indicating profitability challenges.
No significant hedge fund or insider trading trends, showing lack of strong institutional confidence.
Lack of recent news or event-driven catalysts.
In Q4 2025, revenue increased by 66.61% YoY to $147.14M, showing strong top-line growth. However, net income dropped by -121.63% YoY to $17.53M, and EPS fell by -121.57% YoY to $0.11, highlighting profitability issues.
Analysts are mixed on NVAX. Some, like B. Riley and H.C. Wainwright, maintain a Buy rating and have raised price targets to $18 and $16, respectively. Others, like Citi and BofA, maintain Sell or Underperform ratings with lower price targets. The average sentiment is cautious optimism, but with significant risks.
